Mirum Pharmaceuticals, Inc. MIRM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -139.8%-136pp | -4.2%+4.6pp | -8.9%+4.4pp | -13.3%+6.8pp | -20.1%+5.9pp | |
| Net margin | -140.2%-136pp | -4.5%+4.3pp | -8.8%+4.9pp | -13.6%+6.7pp | -20.4%+5.7pp | |
| Returns | ||||||
| Return on equity | -335.8%-327pp | -8.6%+7.2pp | -15.8%+8.4pp | -24.2%+8.9pp | -33.1%+4.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×0.0× | 0.6×0.0× | 0.6×+0.1× | 0.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.1×-0.6× | 2.7×-0.6× | 3.3×+0.2× | 3.1×-0.1× | 3.2×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.12-34.3% | $6.27+22.3% | $5.12-0.1% | $5.13+7.5% | $4.77+0.5% | |
| Valuation | ||||||
| Market capitalization | $5.57B+36.5% | $4.08B+10.8% | $3.68B+45.5% | $2.53B+14.7% | $2.21B+11.2% | |
| Price / sales | 9.8×+2.0× | 7.8×0.0× | 7.8×+1.9× | 5.9×+0.1× | 5.8×-0.1× | |
| Price / book | 23×+10.0× | 13×+0.4× | 12.6×+2.7× | 9.9×+0.5× | 9.5×+0.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mirum Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Mirum Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
